<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02329327</url>
  </required_header>
  <id_info>
    <org_study_id>14-505</org_study_id>
    <nct_id>NCT02329327</nct_id>
  </id_info>
  <brief_title>A Study in Patients With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants</brief_title>
  <official_title>Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portola Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Portola Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the hemostatic efficacy of andexanet alfa in
      patients receiving a factor Xa inhibitor who are experiencing an acute major bleed. The
      safety of andexanet will also be studied.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with excellent or good hemostasis</measure>
    <time_frame>Stopping major bleed at 12 hours from the start of andexanet bolus</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Andexanet</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. Acute major bleeding episode requiring urgent reversal of anticoagulation; defined by
             at least one of the following:

               -  Acute bleeding that is potentially life-threatening, OR

               -  Acute bleeding associated with a fall in hemoglobin level by ≥2 g/dL, OR

               -  Acute bleeding associated with a hemoglobin level of ≤8 g/dL if no baseline
                  hemoglobin is available, OR

               -  Acute bleeding in a critical area or organ such as intraspinal, pericardial, or
                  intracranial.

          2. If bleeding is intracranial or intraspinal, the patient must have undergone a head CT
             or MRI scan demonstrating the bleeding.

          3. Patient received or is believed to have received one of the following within 18 hours
             prior to andexanet administration: apixaban, rivaroxaban, edoxaban or enoxaparin.

          4. For patients with intracranial bleeding, there must be a reasonable expectation that
             andexanet treatment will commence within 2 hours of the baseline imaging evaluation.

        Exclusion:

          1. The patient is scheduled to undergo surgery in less than 12 hours, with the exception
             of minimally invasive surgery/procedures.

          2. A patient with an intracerebral hemorrhage has any of the following:

               -  Glasgow coma score &lt; 7, OR

               -  Intracerebral hematoma &gt; 60 cc as assessed by CT or MRI

          3. Patients with visible, musculoskeletal or intra-articular bleeding as their qualifying
             bleed.

          4. Expected survival of less than 1 month

          5. Recent history (within 2 weeks) of a diagnosed thrombotic event (TE) as follows:
             venous thromboembolism, myocardial infarction, disseminated intravascular coagulation
             (DIC), cerebral vascular accident, transient ischemic attack, unstable angina pectoris
             hospitalization or severe peripheral vascular disease within 2 weeks prior to
             screening.

          6. Severe sepsis or septic shock at the time of Screening.

          7. Pregnant or a lactating female.

          8. Patient has received any of the following drugs or blood products within 7 days of
             Screening:

               -  Vitamin K antagonist (VKA)

               -  Dabigatran

               -  Prothrombin Complex Concentrate products (PCC) or recombinant factor VIIa
                  (rfVIIa)

               -  Whole blood, plasma fractions

          9. Treated with an investigational drug &lt;30 days prior to Screening

         10. Planned administration of PCC, fresh frozen plasma (FFP) or rfVIIa from Screening
             until within 12 hours after the end of the andexanet infusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick Yue, M.D.</last_name>
    <phone>650.246.7000</phone>
    <email>fXaantidote@portola.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650.246.7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Altenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Celle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Detmold</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Hessen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Konstanz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Lubeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Sitee</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Osnabrück</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Sande</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fxaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Caceres</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Stoke on Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-246-7000</phone>
      <email>fXaantidote@portola.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor Xa Inhibitors</keyword>
  <keyword>Major</keyword>
  <keyword>Bleeding</keyword>
  <keyword>Anticoagulant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Factor Xa Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

